• Speaking of which: Has it been third-party tested? Nearly every expert Health spoke to agreed that your CBD products should be tested by a third party to confirm the label's accuracy. This is a real concern in the industry—take the 2017 Journal of the American Medical Association study, for example, which tested 84 CBD products and found that 26% contained lower doses than stated on the bottle. Look for a quality assurance stamp or certificate of analysis from a third party (aka not the actual brand) or check the retailer's website if you don't see it on the product's label.
This article may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.
The 2014 Farm Bill[75] legalized the sale of "non-viable hemp material" grown within states participating in the Hemp Pilot Program.[76] This legislation defined hemp as cannabis containing less than 0.3% of THC delta-9, grown within the regulatory framework of the Hemp Pilot Program.[77] The 2018 Farm Bill allowed for interstate commerce of hemp derived products, though these products still fall under the purview of the FDA.[78][79]
For example, 100mg of isolated CBD may be substantially less effective at alleviating symptoms than 100mg of a whole-plant, cannabis extract that contains CBD. While it may be cheaper and more cost-effective to extract CBD from industrial hemp, users may ultimately experience less benefit due to the absence of clinically significant levels of terpenes and other compounds which are plentiful in cannabis. While high-CBD cultivars of cannabis do contain much higher levels of various cannabinoids and terpenes, there are risks and side effects associated with its use.
This article may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.
We use cookies and similar technologies to improve your browsing experience, personalize content and offers, show targeted ads, analyze traffic, and better understand you. We may share your information with third-party partners for marketing purposes. To learn more and make choices about data use, visit our Advertising Policy and Privacy Policy. By clicking “Accept and Continue” below, (1) you consent to these activities unless and until you withdraw your consent using our rights request form, and (2) you consent to allow your data to be transferred, processed, and stored in the United States.
×